356 related articles for article (PubMed ID: 19522829)
21. Medullary thyroid cancer: a promising model for targeted therapy.
Torino F; Paragliola RM; Barnabei A; Corsello SM
Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
[TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination.
Pfragner R; Skofitsch G; Höger H; Jech M; Rinner B; Siegl V; Niederle B; Gnant M; Friedl J; Stift A
Anticancer Res; 2005; 25(6B):4225-30. PubMed ID: 16309220
[TBL] [Abstract][Full Text] [Related]
23. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.
Machens A; Lorenz K; Dralle H
J Intern Med; 2009 Jul; 266(1):114-25. PubMed ID: 19522830
[TBL] [Abstract][Full Text] [Related]
24. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
25. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
26. Gene therapeutic approaches for medullary thyroid carcinoma treatment.
Drosten M; Pützer BM
J Mol Med (Berl); 2003 Jul; 81(7):411-9. PubMed ID: 12811413
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
29. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
31. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.
Messina M; Robinson BG
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):290-301. PubMed ID: 17315037
[TBL] [Abstract][Full Text] [Related]
32. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
Gujral TS; van Veelen W; Richardson DS; Myers SM; Meens JA; Acton DS; Duñach M; Elliott BE; Höppener JW; Mulligan LM
Cancer Res; 2008 Mar; 68(5):1338-46. PubMed ID: 18316596
[TBL] [Abstract][Full Text] [Related]
33. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
34. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
35. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
[TBL] [Abstract][Full Text] [Related]
36. Medullary thyroid carcinoma and biomarkers: past, present and future.
van Veelen W; de Groot JW; Acton DS; Hofstra RM; Höppener JW; Links TP; Lips CJ
J Intern Med; 2009 Jul; 266(1):126-40. PubMed ID: 19522831
[TBL] [Abstract][Full Text] [Related]
37. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
[TBL] [Abstract][Full Text] [Related]
39. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
40. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
